Convergence Investment Partners’s Novartis NVS Stock Holding History

Convergence Investment Partners’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-622	Closed	-$45K	–	702
2018 Q1	$45K	Buy	+622	New	+$47.4K	0.01%	458
2015 Q4	–	Sell	-3,682	Closed	-$303K	–	366
2015 Q3	$303K	Sell	3,682 -990	-21%	-$88.1K	0.03%	324
2015 Q2	$412K	Sell	4,672 -1,551	-25%	-$142K	0.04%	319
2015 Q1	$550K	Sell	6,223 -847	-12%	-$75.1K	0.08%	309
2014 Q4	$587K	Sell	7,070 -91	-1%	-$7.54K	0.08%	299
2014 Q3	$604K	Buy	7,161 +1,206	+20%	+$97.6K	0.08%	292
2014 Q2	$483K	Sell	5,955 -2,732	-31%	-$215K	0.06%	303
2014 Q1	$662K	Sell	8,687 -2,211	-20%	-$161K	0.1%	263
2013 Q4	$785K	Sell	10,898 -1,935	-15%	-$135K	0.13%	198
2013 Q3	$882K	Sell	12,833 -3,341	-21%	-$221K	0.19%	158
2013 Q2	$1.02M	Buy	+16,174	New	+$1.05M	0.27%	123

Other funds holding NVS

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Convergence Investment Partners's NVS Position: Q2 2018 in Review

Convergence Investment Partners sold out of Novartis (NVS) in Q2 2018, closing a stake of 622 shares — an estimated $45K sold.

Convergence Investment Partners first reported a position in NVS in Q2 2013 and held it in 11 quarters. The position peaked at $1.02M in Q2 2013. 987 funds tracked by Wall St. Rank hold NVS as of Q2 2018.

Convergence Investment Partners reported no remaining Novartis position as of Q2 2018 after selling out during the quarter.
Convergence Investment Partners sold 622 Novartis shares in Q2 2018, an estimated $45K.
Convergence Investment Partners first reported a position in Novartis in Q2 2013 and held it in 11 quarters.
Convergence Investment Partners's Novartis position peaked at $1.02M in Q2 2013.
987 funds tracked by Wall St. Rank held Novartis as of Q2 2018.

Based on Convergence Investment Partners's 13F filing for Q2 2018, filed 7 Aug 2018.